{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=9", "query": { "intervention": "Placebo powder OR higher carbohydrate", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 2369, "total_pages": 237, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+powder+OR+higher+carbohydrate&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:27:10.353Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02610374", "title": "Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Agrarian Diet", "type": "OTHER" }, { "name": "Western-type Diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 90, "start_date": "2016-03", "completion_date": "2020-03", "has_results": false, "last_update_posted_date": "2022-01-21", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02610374" }, { "nct_id": "NCT00531843", "title": "The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "fondaparinux sodium", "type": "DRUG" }, { "name": "sequential compression devices", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Mary Knudson, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2007-12", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2013-12-24", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531843" }, { "nct_id": "NCT00112879", "title": "Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "Refractory Plasma Cell Neoplasm" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "ascorbic acid", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "anti-cytokine therapy", "type": "PROCEDURE" }, { "name": "antiangiogenesis therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "drug resistance inhibition", "type": "PROCEDURE" }, { "name": "growth factor antagonist therapy", "type": "PROCEDURE" }, { "name": "non-specific immune-modulator therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112879" }, { "nct_id": "NCT03003520", "title": "A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-02-28", "completion_date": "2022-04-24", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03003520" }, { "nct_id": "NCT01653886", "title": "Palatability (Energy I Pilot)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Energy Density" ], "interventions": [ { "name": "Breakfast (1-2 hours, in the morning)", "type": "OTHER" }, { "name": "Lunch (1-2 Hours, at midday)", "type": "OTHER" }, { "name": "Dinner (1-2 hours, in the afternoon)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2010-10", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01653886" }, { "nct_id": "NCT00066482", "title": "Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "MESNA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 19, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-17", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066482" }, { "nct_id": "NCT00465569", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Milk Hypersensitivity" ], "interventions": [ { "name": "cow's milk powder", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 20, "start_date": "2006-08", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Durham, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00465569" }, { "nct_id": "NCT07063173", "title": "Bioavailability of Ration Items Containing Tart Cherry Extract", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bioavailability" ], "interventions": [ { "name": "Fruit Bar", "type": "DIETARY_SUPPLEMENT" }, { "name": "Powdered Drink", "type": "DIETARY_SUPPLEMENT" }, { "name": "Commercially available 100% tart cherry juice", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo beverage", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "United States Army Research Institute of Environmental Medicine", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "17 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "17 Years to 39 Years" }, "enrollment_count": 15, "start_date": "2024-06-14", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Natick, Massachusetts", "locations": [ { "city": "Natick", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063173" }, { "nct_id": "NCT05660447", "title": "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Rhegmatogenous Retinal Detachment", "Proliferative Vitreoretinopathy" ], "interventions": [ { "name": "Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]", "type": "DRUG" }, { "name": "Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wills Eye", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-02-06", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660447" }, { "nct_id": "NCT01058135", "title": "Effects of Hi-maize Resistant Starch on Insulin Sensitivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Insulin Resistance" ], "interventions": [ { "name": "Hi-maize starch (Low dose)", "type": "OTHER" }, { "name": "Hi-maize starch (High-dose)", "type": "OTHER" }, { "name": "Control (starch)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ingredion Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 32, "start_date": "2010-01", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2016-04-21", "last_synced_at": "2026-10-14T17:27:10.353Z", "location_count": 1, "location_summary": "Glen Ellyn, Illinois", "locations": [ { "city": "Glen Ellyn", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058135" } ] }